Search Orphan Drug Designations and Approvals
-
| Generic Name: | mifepristone | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Name: | Korlym | ||||||||||||||||
| Date Designated: | 07/05/2007 | ||||||||||||||||
| Orphan Designation: | Treatment of the clinical manifestations of endogenous Cushing's syndrone | ||||||||||||||||
| Orphan Designation Status: | Designated/Approved | ||||||||||||||||
| Sponsor: |
Corcept Therapeutics, Inc. 149 Commonwealth Drive Menlo Park, California 94025 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
| 1 | Generic Name: | mifepristone |
|---|---|---|
| Trade Name: | Korlym | |
| Marketing Approval Date: | 02/17/2012 | |
| Approved Labeled Indication: | for the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. | |
| Exclusivity End Date: | 02/17/2019 | |
| Exclusivity Protected Indication* : | ||
-
